SCOTUS rules agains Amgen, 9-0. An important decision because Amgen wanted to enforce a patent on any monoclonal against a particular target (the PCSK9 receptor), which would have set a terrible precedent.

"This case does not involve those antibody-specific patents. Instead, it involves much broader patents Amgen obtained, which cover every antibody that binds to the same sweet spot and works the same way, a class that includes potentially millions of antibodies."

https://www.scotusblog.com/2023/05/supreme-court-rules-invalid-amgens-patent-on-cholesterol-lowering-drug/